Want to see JP:6099 full AI Analyst Report?
Top Page
Elan Corp.
(6099)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥798.00
▲(9.47% Upside)
Action:Reiterated
Date:02/06/26
The score is driven primarily by strong financial quality (low leverage, consistent growth, solid returns) and supportive valuation (moderate P/E with a meaningful dividend). These positives are partially offset by mixed technical signals, with longer-term trend indicators still weak despite improving near-term momentum.
Positive Factors
Conservative balance sheet / low leverage
Very low debt-to-equity (~0.05 in 2025) and expanding equity provide durable financial flexibility. This reduces refinancing and solvency risk, supports capital allocation for dividends or reinvestment, and better insulates the company from cyclic stress over the next several quarters.
Negative Factors
Margin compression
Trend of declining operating and net margins versus earlier years suggests rising cost pressure or adverse mix. If structural, this can erode long-term earnings power and free cash flow margins, limiting the company's ability to expand margins even with steady revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low debt-to-equity (~0.05 in 2025) and expanding equity provide durable financial flexibility. This reduces refinancing and solvency risk, supports capital allocation for dividends or reinvestment, and better insulates the company from cyclic stress over the next several quarters.
Read all positive factors
Elan Corp. (6099) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥44.56B
Dividend Yield1.77%
Average Volume (3M)89.05K
Price to Earnings (P/E)15.3
Beta (1Y)0.53
Revenue Growth14.79%
EPS Growth20.14%
CountryJP
Employees676
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)39.63
Shares Outstanding60,600,000
10 Day Avg. Volume77,090
30 Day Avg. Volume89,046
Financial Highlights & Ratios
PEG Ratio0.90
Price to Book (P/B)3.03
Price to Sales (P/S)0.79
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)52.9
Revenue Forecast (FY)¥60.50B
Elan Corp. Business Overview & Revenue Model
Company Description
Elan Corporation operates within the healthcare sector, specializing in nursing and medical services. The company offers a rental and laundry service for crucial daily items such as clothing, towels, and diapers, primarily catering to patients in ...
Elan Corp. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.51B | 55.45B | 47.51B | 41.43B | 36.26B | 31.64B |
| Gross Profit | 11.11B | 11.87B | 10.72B | 9.75B | 9.03B | 7.88B |
| EBITDA | 4.87B | 5.59B | 4.49B | 3.85B | 3.53B | 2.92B |
| Net Income | 2.40B | 2.77B | 2.35B | 2.52B | 2.08B | 1.91B |
Balance Sheet | ||||||
| Total Assets | 23.13B | 26.23B | 21.61B | 18.99B | 16.07B | 13.95B |
| Cash, Cash Equivalents and Short-Term Investments | 5.62B | 6.85B | 6.85B | 5.49B | 6.04B | 5.63B |
| Total Debt | 791.30M | 765.20M | 86.57M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 10.08B | 11.55B | 9.10B | 8.18B | 7.08B | 6.46B |
| Stockholders Equity | 12.86B | 14.44B | 12.50B | 10.81B | 8.99B | 7.48B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.18B | 3.62B | 1.59B | 1.23B | 2.03B |
| Operating Cash Flow | 0.00 | 4.29B | 4.50B | 1.78B | 1.58B | 2.11B |
| Investing Cash Flow | 0.00 | -3.39B | -2.23B | -1.66B | -624.51M | -357.68M |
| Financing Cash Flow | 0.00 | -906.86M | -849.53M | -667.09M | -552.96M | -614.15M |
Elan Corp. Technical Analysis
Positive
729.00
Price Trends
716.00
Positive
720.86
Positive
732.99
Positive
Market Momentum
6.09
Negative
63.43
Neutral
93.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6099, the sentiment is Positive. The current price of 729 is above the 20-day moving average (MA) of 707.55, above the 50-day MA of 716.00, and below the 200-day MA of 732.99, indicating a bullish trend. The MACD of 6.09 indicates Negative momentum. The RSI at 63.43 is Neutral, neither overbought nor oversold. The STOCH value of 93.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6099.
Elan Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥44.56B | 15.28 | 20.80% | 1.77% | 14.79% | 20.14% | |
72 Outperform | ¥43.92B | 12.04 | ― | 2.63% | 3.49% | -14.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥5.52B | 52.63 | ― | 4.07% | 4.85% | -85.27% | |
51 Neutral | ¥2.37B | 20.57 | ― | 2.56% | -6.54% | -69.23% | |
46 Neutral | ¥4.47B | 14.69 | ― | 1.41% | 16.83% | -45.33% |
* Healthcare Sector Average
JP:6099
Elan Corp.
737.00
-24.29
-3.19%
JP:2373
Care Twentyone Corporation
410.00
18.26
4.66%
JP:2425
Care Service Co., Ltd.
624.00
-156.58
-20.06%
JP:6062
Charm Care Corporation
1,347.00
71.16
5.58%
JP:7061
Japan Hospice Holdings Inc.
527.00
-536.07
-50.43%
Elan Corp. Corporate Events
Elan Restores Prime Market Compliance by Lifting Tradable Share Ratio
Feb 4, 2026
ELAN reported that as of December 31, 2025 it now satisfies every TSE Prime Market continued listing requirement, largely by boosting its tradable share ratio above the 35% threshold through reclassifying shares once held by former CEO Hideharu Sa...
Elan Lifts Year-End Dividend to ¥15 Per Share
Feb 4, 2026
Elan’s board approved a year-end dividend of ¥15 per share for the fiscal year ended December 31, 2025, matching prior guidance and raising the total payout to ¥908 million, up from ¥787 million for the previous year. The deci...
Elan Posts Double-Digit Growth and Raises Dividend on Expanded Patient Services
Feb 4, 2026
Elan’s 2025 consolidated revenue rose 16.7% to ¥55.4 billion and operating profit climbed 19.5% to ¥4.27 billion, underpinned by higher patient-support service adoption, while net income grew 17.5% to ¥2.77 b...
Elan Corporation Announces Leadership and Departmental Restructuring
Dec 18, 2025
Elan Corporation has announced a series of executive and departmental personnel changes effective January 1, 2026, aimed at streamlining its operations and reinforcing its leadership structure. The realignment includes changes in responsibilities ...
Elan Corp. Reports Strong Financial Growth and Expansion
Nov 7, 2025
Elan Corp. reported a notable increase in its financial performance for the nine months ended September 30, 2025, with net sales rising by 16.9% and net profit attributable to owners increasing by 10.4% compared to the previous year. The company a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.